- Trials with a EudraCT protocol (158)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (4)
158 result(s) found for: Cardiac Arrhythmia.
Displaying page 3 of 8.
EudraCT Number: 2015-005663-17 | Sponsor Protocol Number: SB3-G31-BC-E | Start Date*: 2016-04-11 | ||||||||||||||||
Sponsor Name:Samsung Bioepis Co., Ltd. | ||||||||||||||||||
Full Title: A Long-term Follow-up Study for Cardiac Safety in the Patients with HER2 Positive Early or Locally Advanced Breast Cancer Who Have Completed the SB3-G31-BC | ||||||||||||||||||
Medical condition: Subjects with primary HER2 positive early or locally advanced breast cancer, who have completed the study treatment of SB3-G31-BC. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||
Trial protocol: CZ (Completed) FR (Completed) BG (Completed) RO (Prematurely Ended) PL (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-000721-11 | Sponsor Protocol Number: CHPAU2019/03 | Start Date*: 2020-09-24 | ||||||||||||||||
Sponsor Name:Centre hospitalier de PAU | ||||||||||||||||||
Full Title: Management of Anticoagulant Therapy monitored by an implantable device with telecardiology in patients with Acute Coronary Syndrome associated with de novo atrial Fibrillation Arrhythmia (SCA-FA): ... | ||||||||||||||||||
Medical condition: acute coronary syndrome and atrial fibrillation | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-005688-36 | Sponsor Protocol Number: SCIVF2021 | Start Date*: 2022-09-19 |
Sponsor Name:Amsterdam UMC | ||
Full Title: Quinidine versus verapamil in short-coupled idiopathic ventricular fibrillation: An open label, randomized crossover pilot trial | ||
Medical condition: Short-coupled idiopathic ventricular fibrillation is a rare syndrome and subtype of idiopathic ventricular fibrillation that is characterized by ventricular fibrillation or polymorphic ventricular ... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2009-012581-32 | Sponsor Protocol Number: SB-480848/033 | Start Date*: 2010-01-28 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development, Ltd | |||||||||||||
Full Title: A Clinical Outcomes Study of Darapladib versus Placebo in Subjects Following Acute Coronary Syndrome to Compare the Incidence of Major Adverse Cardiovascular Events (MACE). (Short title: The Stabi... | |||||||||||||
Medical condition: after recent Acute Coronary Syndrome (ACS) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) DE (Completed) BE (Completed) ES (Completed) NL (Completed) SE (Completed) DK (Completed) HU (Completed) CZ (Completed) SK (Completed) PL (Completed) BG (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-000480-27 | Sponsor Protocol Number: UCC-IGF-001 | Start Date*: 2011-06-03 | |||||||||||
Sponsor Name:University College Cork | |||||||||||||
Full Title: A Randomised Trial Evaluating the Safety and Efficacy of a Single Low Dose of Intracoronary Insulin-like Growth Factor-1 Following Percutaneous Coronary Intervention for ST-Elevation Acute Myocardi... | |||||||||||||
Medical condition: ST Elevation Myocardial Infarction | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-020497-41 | Sponsor Protocol Number: ANG.AMI-IC001 | Start Date*: 2013-02-13 | |||||||||||
Sponsor Name:Mesoblast, Inc. | |||||||||||||
Full Title: A prospective, double blind, randomized, placebo-controlled clinical trial of intracoronary infusion of immunoselected, bone marrow-derived Stro3 mesenchymal precursor cells (MPC) in the treatment ... | |||||||||||||
Medical condition: ST-elevation myocardial infarction | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) NL (Completed) DK (Completed) SE (Completed) CZ (Completed) AT (Prematurely Ended) PL (Completed) IT (Prematurely Ended) ES (Completed) PT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-001853-89 | Sponsor Protocol Number: CLI-043 | Start Date*: 2006-07-07 |
Sponsor Name:Vion Pharmaceuticals, Inc | ||
Full Title: A phase II study of Cloretazine for elderly patients with de novo poor risk acute myelogenous leukemia. | ||
Medical condition: Acute Myelogenous Leukemia | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) DE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2013-004317-40 | Sponsor Protocol Number: ADRAMIO001 | Start Date*: 2014-06-23 | ||||||||||||||||||||||||||
Sponsor Name:The Heart Centre, Rigshospitalet | ||||||||||||||||||||||||||||
Full Title: Adrenaline versus amiodarone for out of hospital cardiac arrest due to shockable rhythms (ventricular fibrillation and pulseless ventricular tachycardia) - ADRAMIO. A randomized, double blind, mu... | ||||||||||||||||||||||||||||
Medical condition: Out of hospital cardiac arrest due to ventricular fibrillation. | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: DK (Prematurely Ended) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-003529-17 | Sponsor Protocol Number: ARCADIA | Start Date*: 2008-11-17 | |||||||||||
Sponsor Name:IST. DI RICERCHE FARMACOLOG. M. NEGRI | |||||||||||||
Full Title: A PROSPECTIVE, RANDOMIZED, OPEN LABEL, BLINDED END-POINT (PROBE) TRIAL TO EVALUATE WHETHER, AT COMPARABLE BLOOD PRESSURE CONTROL, ACE INHIBITOR THERAPY MORE EFFECTIVELY THAN NON RAS INHIBITOR THERA... | |||||||||||||
Medical condition: End stage renal disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-006614-37 | Sponsor Protocol Number: CryoStopPersAF | Start Date*: 2022-05-11 | |||||||||||
Sponsor Name:Region Örebro | |||||||||||||
Full Title: First-line cryoablation for early treatment of Persistent Atrial Fibrillation – a randomized study comparing early trigger isolation using the Cryoballoon versus antiarrhythmic medication. | |||||||||||||
Medical condition: Persistent symptomatic atrial fibrillation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-004727-18 | Sponsor Protocol Number: CORUNO/II/05.1 | Start Date*: 2008-06-20 | |||||||||||
Sponsor Name:THERABEL PHARMACEUTICAL Ltd | |||||||||||||
Full Title: EFFECT OF MOLSIDOMINE 16 MG ADMINISTERED ONCE-DAILY AS A LONG-TERM ADD-ON TREATMENT, ON ATHEROSCLEROSIS PROGRESSION AND INFLAMMATORY BIOMARKERS IN PATIENTS HOSPITALIZED FOR ACUTE CORONARY SYNDROME. | |||||||||||||
Medical condition: Randomized, double-blind, placebo-controlled, add-on study in two parallel groups. Patients admitted for Non ST Segment Elevation Acute Coronary Syndromes will undergo a coronary angiography accord... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-004051-19 | Sponsor Protocol Number: IM101-042 | Start Date*: 2005-05-13 |
Sponsor Name:Bristol-Myers Squibb International Corporation | ||
Full Title: A Phase IIB, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept in Combination Therapy with Glucocorticosteroids vs. Placebo plus Gluc... | ||
Medical condition: SYSTEMIC LUPUS ERYTHEMATOSUS, NOS | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) GB (Prematurely Ended) SE (Prematurely Ended) BE (Completed) AT (Completed) IT (Prematurely Ended) | ||
Trial results: Removed from public view |
EudraCT Number: 2017-001507-76 | Sponsor Protocol Number: BRONCHIOLE2017 | Start Date*: 2017-09-20 |
Sponsor Name:Region Örebro län | ||
Full Title: Beta-blockeRs tO patieNts with CHronIc Obstructive puLmonary diseasE (BRONCHIOLE) A pragmatic clinical trial with partial registry-based follow-up | ||
Medical condition: Chronic Obstructive Pulmonary disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2018-004672-35 | Sponsor Protocol Number: PACS2019 | Start Date*: 2020-01-10 |
Sponsor Name:Institution for Clinical Science, Karolinska Institutet | ||
Full Title: Open heart surgery – does it have to hurt that much? PACS – Parasternal After Cardiac Surgery. A prospective randomised study to assess the analgesic effect of a continuous bilateral parasternal bl... | ||
Medical condition: The analgesic effect of continuous bilateral parasternal infusion of local anaesthetic after open cardiac surgery. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2022-002686-15 | Sponsor Protocol Number: CHUBX2021/25 | Start Date*: 2022-10-18 |
Sponsor Name:CHU de Bordeaux | ||
Full Title: Effectiveness of an Optimisation Strategy for Emergency Tracheal Intubation on postintubation Morbidity: A cluster randomized controlled trial | ||
Medical condition: respiratory distress | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2011-002789-18 | Sponsor Protocol Number: RAF-01 | Start Date*: 2011-11-15 | |||||||||||
Sponsor Name:Menarini Ricerche S.p.A | |||||||||||||
Full Title: A RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, DOSE-RANGING PHASE II STUDY ASSESSING RANOLAZINE IN THE MAINTENANCE OF SINUS RHYTHM AFTER ELECTRICAL CARDIOVERSION IN PATIENTS WITH NON... | |||||||||||||
Medical condition: NON-PERMANENT ATRIAL FIBRILLATION | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Completed) GB (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-001781-14 | Sponsor Protocol Number: POX-MVA-005 | Start Date*: 2006-04-11 | |||||||||||
Sponsor Name:Bavarian Nordic A/S | |||||||||||||
Full Title: A partially randomized, partially double-blind, placebo-controlled Phase II non-inferiority study to evaluate immunogenicity and safety of one and two doses of MVA-BN (IMVAMUNE™) smallpox vaccine i... | |||||||||||||
Medical condition: Healthy subjects - prevention of smallpox infection | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-001063-23 | Sponsor Protocol Number: 012357 | Start Date*: 2018-06-14 | |||||||||||
Sponsor Name:Queen Mary Innovation Centre, Queen Mary University of London | |||||||||||||
Full Title: PHASE II STUDY ASSESSING THE COMBINED USE OF AUTOLOGOUS BONE MARROW DERIVED MONONUCLEAR CELLS AND G-CSF WITH PERCUTANEOUS CIRCULATORY ASSISTANCE IN THE TREATMENT OF DILATED CARDIOMYOPATHY | |||||||||||||
Medical condition: Heart failure is caused by a cardiomyopathy, which is defined as a disorder of the heart muscle. Dilated cardiomyopathy (DCM) is characterised by enlargement of the ventricles and impaired systolic... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-006404-11 | Sponsor Protocol Number: PERFECT001(M-2006-144) | Start Date*: 2008-03-19 | |||||||||||
Sponsor Name:Miltenyi Biotec GmbH | |||||||||||||
Full Title: INTRAMYOCARDIAL TRANSPLANTATION OF BONE MARROW STEM CELLS FOR IMPROVEMENT OF POST-INFARCT MYOCARDIAL REGENERATION IN ADDITION TO CABG SURGERY: a controlled prospective, randomized, double blinded m... | |||||||||||||
Medical condition: Coronary artery disease after myocardial infarction with an indication for CABG surgery | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-000042-30 | Sponsor Protocol Number: GS-US-372-1234 | Start Date*: 2015-05-18 | |||||||||||
Sponsor Name:Gilead Sciences, Inc. | |||||||||||||
Full Title: A Phase 3, Single-Blind Study to Evaluate the Effect of Eleclazine (GS-6615) on Shortening of the QT Interval, Safety, and Tolerability in Subjects with Long QT-3 Syndrome | |||||||||||||
Medical condition: Subjects with an established diagnosis of LQT3. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) DE (Prematurely Ended) NL (Prematurely Ended) ES (Prematurely Ended) FI (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
